Inflammatory Bowel Diseases

Skip Navigation LinksHome > September 2013 - Volume 19 - Issue 10 > Infliximab Reduces Hospitalizations and Surgery Intervention...
Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0b013e31829936c2
Original Clinical Articles

Infliximab Reduces Hospitalizations and Surgery Interventions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Costa, João MD, PhD*,†,‡; Magro, Fernando MD, PhD§,‖,¶; Caldeira, Daniel MD; Alarcão, Joana MPharm*,†; Sousa, Rita MPharm*; Vaz-Carneiro, António MD, PhD*,‡

Supplemental Author Material
Collapse Box


Background: We systematically reviewed infliximab benefit in reducing hospitalizations and/or major surgery rates in patients with inflammatory bowel disease (IBD).

Methods: A literature search to May 2012 was performed to identify all studies (experimental and observational) evaluating patients with IBD treated with infliximab and providing data on hospitalizations and/or major surgery rates. Three reviewers independently performed studies' selection, quality assessment, and data extraction. Analyses were carried according to study design (randomized clinical trials [RCTs] and observational studies) and IBD type (Crohn's disease [CD] and ulcerative colitis [UC]). Random-effects meta-analysis was used to derive pooled and 95% confidence intervals (CIs) estimates of odds ratios (OR). Heterogeneity was assessed with I2 test.

Results: Twenty-seven eligible studies were included (9 RCTs and 18 observational studies). Infliximab reduced hospitalization risk, both in pooled RCTs (OR, 0.51; 95% CI 0.40–0.65; I2 = 0%) and results of observational studies (OR, 0.29, 95% CI, 0.19–0.43; I2 = 87%), without differences between CD and UC. Infliximab reduced surgery risk in pooled RCTs results, both in CD (OR, 0.31; 95% CI, 0.15–0.64; I2 = 0%) and UC (OR, 0.57; 95% CI, 0.37–0.88; I2 = 0%). Pooled estimate from observational studies favored infliximab for patients with CD (OR, 0.32; 95% CI, 0.21–0.49; I2 = 77%), but not for patients with UC.

Conclusions: The best evidence available points toward a reduction of the risk of hospitalization and major surgery requirement in patients with IBD treated with infliximab. This impact is clinically and economically relevant because hospitalization and surgery are considered to be markers of disease severity and significantly contribute to the total direct costs associated with IBD.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.